asjat gapur retinopatia diabetes - Progression of retinopathy with glucagonlike peptide1 tata laksana diabetes receptor agonists with cardiovascular benefits in type 2 diabetes A systematic review and metaanalysis J Diabetes Complications 2022 Aug 17369108285 doi 101016jjdiacomp2022108285 Online ahead of print Author Progression of retinopathy with glucagonlike peptide1 receptor GLP1R as a Target for the Treatment of Diabetic Retinopathy Friend or Impact of GLP1 Agonists and SGLT2 Inhibitors on Diabetic Retinopathy Diabetic Retinopathy A Position Statement by the American Diabetes HbA American Diabetes Association Risk Factors for the Development of Retinopathy in Prediabetes PubMed An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagonlike peptide1 receptor agonist GLP1 RA semaglutide whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide A total of 6481 patients were identified in the GLP1 cohort and the SGLT2 inhibitor cohort after propensity score matching At 1 and 3 years after initiation of therapy a higher rate of progression of PDR was noted RR 126 CI 104151 P 017 at 1 year RR 1284 CI 111499 P 002 at 3 years in the GLP1 agonist cohort compared to the SGLT2 inhibitor cohort GLP1 receptor agonists and diabetic retinopathy A metaanalysis of Progression of retinopathy with glucagonlike peptide1 receptor Lowering blood pressure has been shown to decrease retinopathy progression in people with type 2 diabetes although tight targets systolic blood pressure 120 mmHg do not impart additional benefit over targets of 140 mmHg 910In patients with dyslipidemia retinopathy progression may be slowed by the addition of fenofibrate particularly with very mild nonproliferative diabetic Objective To determine glycemic and nonglycemic risk factors that contribute to the presence of diabetic retinopathy DR before and after the onset of type 2 diabetes T2D Research design and methods During the Diabetes Prevention Program DPP and DPP Outcome Study DPPOS we performed fundus photography over time in adults melabic obat herbal diabetes at high risk for developing T2D including after they developed The Effect of GlucagonLike Peptide1 Receptor Agonists on Diabetic In the last decade glucagonlike peptide1 receptor agonists GLP1 RAs have been demonstrated to be effective options for the treatment of type 2 diabetes mellitus T2DM as they are proven to lower HbA1c levels and promote weight loss while having a low risk of hypoglycemia 4 Since gaining FDA approval in 2005 the availability of GLP1 RAs for clinical use has increased significantly 4 Diabetic retinopathy is a leading cause of vision loss globally and develops in response to prolonged exposure to hyperglycemia Despite clear evidence that nearnormalization of blood glucose levels reduces the longterm risk of diabetic retinopathy transient worsening of preexisting retinopathy has also been demonstrated when glucose control is intensified 35 typically with The progression and development of DR is associated with several risk factors including duration of diabetes poor glycemic control and poorly controlled hypertension 1 2 Glucagonlike peptide1 receptor agonists GLP1RA are a class of medications being used with increased frequency as a secondline treatment in the management of type 2 The study aimed to examine the effect of GLP1RA on DR in type 2 diabetes T2DM in RCTs with or without CV benefits and distinguish the effect by major confounders Methods We conducted electronic searches of multiple databases and a manual search using references lists We included 13 RCTs examining the effect of GLP1 RA on health outcomes Diabetic retinopathy DR is the most common complication of diabetes and remains the leading cause of blindness among workingage individuals in developed countries 13DR prevalence in the diabetic population is approximately onethird and 10 have visionthreatening states such as diabetic macular edema or proliferative DR In addition the presence and progression of DR is At a glance factsheet GLP1 how to control diabetes fast receptor agonists and DiabetesontheNet
diabetes boleh minum madu gak
diabetes mellitus prevalence worldwide in country pdf
